Pharmaceutical Drugs Development Annual Review by Key Companies, Sales, Trends and Competitive Analysis in 2024
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
This report investigates the year 2024 in the pharmaceutical industry from the standpoint of drug development. It provides a high-level analysis of key trends and movements within the industry via regulatory, clinical, and market-based analysis, allowing you to discern the large-scale changes and how best to pivot to prioritize them within your sector.
Scope
This 46-page report gives important, expert insight you won’t find in any other source. 21 figures throughout the report illustrate major points and trends in future pharmaceutical sales forecasts and company pipelines. This report is required reading for –
• Investors that want to understand past trends impacting the biopharmaceutical industry as well as identifying companies to invest in
• Companies that are interested in entering the biopharmaceutical space and where best to focus on
• Large pharma companies with investment groups or BD teams looking to see which companies lead the industry in the past and how they led
• Small and medium pharma who want to focus their drug portfolio on future trends and are looking for partnership opportunities
Reasons to Buy
Insights on how drug development in 2024 may impact future approvals
Insights on how drug approvals in 2024 may impact future drug development and approval trends
Sales and regulatory-based insights into 2024 covering various drugs and companies
Merck & Co
Novartis AG
Johnson & Johnson
Abbvie
F.Hoffman-La Roche Ltd
Bristol-Myers Squibb Co
Astrazeneca Plc
GSK plc
Bristol Myers-Squibb Co
Sanofi
Table of Contents
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Pharmaceuticals reports